No matter the pathogen—virus, bacterium or fungus—many "pick a specific type of lock" on the surface of cells, which allows the microbe to break and enter into the inner sanctum of the host's genome.
Cell-penetrating peptides (CPPs) have attracted great interest as delivery vehicles in medicine, with potential for the development of novel therapeutic agents or cosmetic products. Biological membranes are typically impermeable ...
Research led by the Hebrew University of Jerusalem, Israel, has found a potential solution to side effects that interfere with cancer treatment. In the paper, "Preventing skin toxicities induced by EGFR inhibitors by topically ...
Researchers have shown for the first time that a crucial interface in a protein that drives cancer growth could act as a target for more effective treatments.
Mar 19, 2024
0
47
The Organoid group at the Hubrecht Institute has identified a new link between FBXW7 mutations and epidermal growth factor receptor (EGFR) signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such ...
Mar 18, 2024
0
20
Targeting two brain tumor-associated proteins—rather than one—with CAR T cell therapy shows promise as a strategy for reducing solid tumor growth in patients with recurrent glioblastoma (GBM), an aggressive form of brain ...
Mar 13, 2024
0
89
Lung tumors called adenocarcinomas sometimes respond to initially effective treatments by transforming into a much more aggressive small cell lung cancer (SCLC) that spreads rapidly and has few options for treatment. Researchers ...
Feb 8, 2024
0
10
The Organoid Group (Hubrecht Institute) and the Rare Cancers Genomics Team (IARC/WHO) found a way to grow samples of different types of neuroendocrine tumors (NETs) in the lab. While generating their new model, the researchers ...
Dec 11, 2023
0
14
Researchers at Vanderbilt University Medical Center for the first time have shown that activation of the epidermal growth factor receptor (EGFR) is essential for the development of kidney fibrosis, tissue scarring following ...
Nov 22, 2023
0
21
Researchers at MUSC Hollings Cancer Center believe that some drugs already approved by the FDA or currently in clinical trials could be repurposed for certain breast cancer patients whose cancer has become resistant to standard ...
Nov 2, 2023
0
42
